



Universiteit
Leiden
The Netherlands

Substrate adaptability of β -lactamase

Sun, J.

Citation

Sun, J. (2024, February 20). *Substrate adaptability of β -lactamase*. Retrieved from <https://hdl.handle.net/1887/3719631>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3719631>

Note: To cite this publication please use the final published version (if applicable).

References

- 1 De Vries, H. *Species and varieties: their origin by mutation*. (Open Court, 1904).
- 2 Bloom, J. D., Wilke, C. O., Arnold, F. H. & Adami, C. Stability and the evolvability of function in a model protein. *Biophysical Journal* **86**, 2758-2764 (2004).
- 3 Romero, P. A. & Arnold, F. H. Exploring protein fitness landscapes by directed evolution. *Nature reviews Molecular cell biology* **10**, 866-876 (2009).
- 4 Payne, J. L. & Wagner, A. The robustness and evolvability of transcription factor binding sites. *Science* **343**, 875-877 (2014).
- 5 Dellus-Gur, E., Toth-Petroczy, A., Elias, M. & Tawfik, D. S. What makes a protein fold amenable to functional innovation? Fold polarity and stability trade-offs. *Journal of molecular biology* **425**, 2609-2621 (2013).
- 6 Kimura, M. The role of compensatory neutral mutations in molecular evolution. *Journal of Genetics* **64**, 7-19 (1985).
- 7 Smock, R. G., Yadid, I., Dym, O., Clarke, J. & Tawfik, D. S. De novo evolutionary emergence of a symmetrical protein is shaped by folding constraints. *Cell* **164**, 476-486 (2016).
- 8 Tawfik, D. S. Accuracy-rate tradeoffs: how do enzymes meet demands of selectivity and catalytic efficiency? *Current opinion in chemical biology* **21**, 73-80 (2014).
- 9 Arnold, F. H., Wintrode, P. L., Miyazaki, K. & Gershenson, A. How enzymes adapt: lessons from directed evolution. *Trends in biochemical sciences* **26**, 100-106 (2001).
- 10 Miyazaki, K., Wintrode, P. L., Grayling, R. A., Rubingh, D. N. & Arnold, F. H. Directed evolution study of temperature adaptation in a psychrophilic enzyme. *Journal of molecular biology* **297**, 1015-1026 (2000).
- 11 Chirumamilla, R. R., Muralidhar, R., Marchant, R. & Nigam, P. Improving the quality of industrially important enzymes by directed evolution. *Molecular and Cellular Biochemistry* **224**, 159-168 (2001).
- 12 Arnold, F. H. & Volkov, A. A. Directed evolution of biocatalysts. *Current opinion in chemical biology* **3**, 54-59 (1999).
- 13 Kuchner, O. & Arnold, F. H. Directed evolution of enzyme catalysts. *Trends*

References

- in biotechnology* **15**, 523-530 (1997).
- 14 Eigen, M. Macromolecular evolution: Dynamical ordering in sequence space. *Berichte der Bunsengesellschaft für physikalische Chemie* **89**, 658-667 (1985).
 - 15 Kauffman, S. A. *The origins of order: Self-organization and selection in evolution*. (Oxford University Press, USA, 1993).
 - 16 Barrowclough, G. F. (Oxford University Press, 1991).
 - 17 Delagrave, S. & Youvan, D. C. Searching sequence space to engineer proteins: exponential ensemble mutagenesis. *Bio/Technology* **11**, 1548-1552 (1993).
 - 18 Arkin, A. P. & Youvan, D. C. An algorithm for protein engineering: simulations of recursive ensemble mutagenesis. *Proceedings of the National Academy of Sciences* **89**, 7811-7815 (1992).
 - 19 Ling, L. L., Keohavong, P., Dias, C. & Thilly, W. G. Optimization of the polymerase chain reaction with regard to fidelity: modified T7, Taq, and vent DNA polymerases. *Genome Research* **1**, 63-69 (1991).
 - 20 Cadwell, R. C. & Joyce, G. F. Randomization of genes by PCR mutagenesis. *Genome research* **2**, 28-33 (1992).
 - 21 Lin-Goerke, J. L., Robbins, D. J. & Burczak, J. D. PCR-based random mutagenesis using manganese and reduced dNTP concentration. *Biotechniques* **23**, 409-412 (1997).
 - 22 Zhao, H., Moore, J., Volkov, A. & Arnold, F. Methods for optimizing industrial enzymes by directed evolution. *Manual of industrial microbiology and biotechnology*, 597-604 (1999).
 - 23 Arnold, F. H. Combinatorial and computational challenges for biocatalyst design. *Nature* **409**, 253-257 (2001).
 - 24 Zhao, H., Chockalingam, K. & Chen, Z. Directed evolution of enzymes and pathways for industrial biocatalysis. *Current opinion in biotechnology* **13**, 104-110 (2002).
 - 25 Barberis, I., Bragazzi, N. L., Galluzzo, L. & Martini, M. The history of tuberculosis: from the first historical records to the isolation of Koch's bacillus. *Journal of preventive medicine and hygiene* **58**, E9 (2017).
 - 26 Nerlich, A. G., Haas, C. J., Zink, A., Szeimies, U. & Hagedorn, H. G. Molecular evidence for tuberculosis in an ancient Egyptian mummy. *The Lancet* **350**, 1404 (1997).
 - 27 Crubézy, E. *et al.* Identification of Mycobacterium DNA in an Egyptian Pott's disease of 5400 years old. *Comptes Rendus de l'Académie des Sciences-Series III-Sciences de la Vie* **321**, 941-951 (1998).

References

- 28 Dawson, K. *'The captain of all these men of death': aspects of the medical history of tuberculosis: a thesis presented in partial fulfilment of the requirements for the degree of Master of Public Health at Massey University, Manawatu, New Zealand*, Massey University, (2017).
- 29 Mahito, F. The Romantic Images of Tuberculosis: A Cultural History of a Disease. *Academia Sinica*, 1-27 (2000).
- 30 Chalke, H. The impact of tuberculosis on history, literature and art. *Medical history* **6**, 301-318 (1962).
- 31 Black, A. Even in Death she is Beautiful: Confronting Tuberculosis in Art, Literature and Medicine. (2022).
- 32 Bagechi, S. WHO's Global Tuberculosis Report 2022. *The Lancet Microbe* **4**, e20 (2023).
- 33 Daniel, T. M. The history of tuberculosis. *Respiratory medicine* **100**, 1862-1870, doi:10.1016/j.rmed.2006.08.006 (2006).
- 34 Schatz, A., Bugle, E. & Waksman, S. A. Streptomycin, a substance exhibiting antibiotic activity against gram-positive and gram-negative bacteria.*. *Proceedings of the Society for Experimental Biology and Medicine* **55**, 66-69 (1944).
- 35 Lehmann, J. Vol. 90 953-956 (American Lung Association, 1964).
- 36 Sharma, S. & Mohan, A. Multidrug-resistant tuberculosis. *Indian Journal of Medical Research* **120**, 354-376 (2004).
- 37 Mitchison, D. A. The diagnosis and therapy of tuberculosis during the past 100 years. *American journal of respiratory and critical care medicine* **171**, 699-706 (2005).
- 38 Steele, M. A. & Des Prez, R. M. The role of pyrazinamide in tuberculosis chemotherapy. *Chest* **94**, 845-850 (1988).
- 39 Abraham, E. P. & Chain, E. An enzyme from bacteria able to destroy penicillin. *Nature* **146**, 837-837 (1940).
- 40 Citri, N. & Pollock, M. R. The biochemistry and function of β -lactamase (penicillinase). *Adv. enzymol.* **28**, 237-323 (1966).
- 41 Bush, K. Past and present perspectives on β -lactamases. *Antimicrobial agents and chemotherapy* **62**, 10.1128/aac. 01076-01018 (2018).
- 42 Zhang, g. & Hao, Q. Crystal structure of NDM-1 reveals a common β -lactam hydrolysis mechanism. *The FASEB Journal* **25**, 2574-2582 (2011).
- 43 Datta, N. & Kontomichalou, P. Penicillinase Synthesis Controlled By Infectious R Factors In Enterobacteriaceae. *Nature* **208**, 239-241, doi:10.1038/208239a0 (1965).

References

- 44 Davies, J. & Davies, D. Origins and evolution of antibiotic resistance. *Microbiology and molecular biology reviews* : *MMBR* **74**, 417-433, doi:10.1128/membr.00016-10 (2010).
- 45 Nielsen, J. B. & Lampen, J. O. Membrane-bound penicillinases in Gram-positive bacteria. *The Journal of biological chemistry* **257**, 4490-4495 (1982).
- 46 Sawai, T., Mitsunashi, S. & Yamagishi, S. Drug Resistance of Enteric Bacteria: XIV. Comparison of β -Lactamases in Gram-negative Rod Bacteria Resistant to α -Aminobenzylpenicillin. *Japanese journal of microbiology* **12**, 423-434 (1968).
- 47 Huovinen, P., Huovinen, S. & Jacoby, G. Sequence of PSE-2 beta-lactamase. *Antimicrobial agents and chemotherapy* **32**, 134-136 (1988).
- 48 Ambler, R. P. The structure of β -lactamases. *Philosophical Transactions of the Royal Society of London. B, Biological Sciences* **289**, 321-331 (1980).
- 49 Jaurin, B. & Grundström, T. ampC cephalosporinase of Escherichia coli K-12 has a different evolutionary origin from that of beta-lactamases of the penicillinase type. *Proceedings of the National Academy of Sciences* **78**, 4897-4901 (1981).
- 50 Bush, K. & Jacoby, G. A. Updated Functional Classification of β -Lactamases. *Antimicrobial Agents and Chemotherapy* **54**, 969-976, doi:doi:10.1128/aac.01009-09 (2010).
- 51 Bush, K. Characterization of beta-lactamases. *Antimicrobial agents and chemotherapy* **33**, 259-263 (1989).
- 52 Massova, I. & Mobashery, S. Kinship and diversification of bacterial penicillin-binding proteins and β -lactamases. *Antimicrobial agents and chemotherapy* **42**, 1-17 (1998).
- 53 FINCH, R. β -Lactam antibiotics and mycobacteria. *Journal of Antimicrobial Chemotherapy* **18**, 6-8, doi:10.1093/jac/18.1.6 (1986).
- 54 Kasik, J. E. THE NATURE OF MYCOBACTERIAL PENICILLINASE. *The American review of respiratory disease* **91**, 117-119, doi:10.1164/arrd.1965.91.1.117 (1965).
- 55 Lohans, C. T. *et al.* A New Mechanism for β -Lactamases: Class D Enzymes Degrade 1 β -Methyl Carbapenems through Lactone Formation. *Angewandte Chemie* **130**, 1296-1299 (2018).
- 56 Page, M. I. & Badarau, A. The mechanisms of catalysis by metallo beta-lactamases. *Bioinorganic chemistry and applications* **2008**, 576297, doi:10.1155/2008/576297 (2008).
- 57 Bush, K., Jacoby, G. A. & Medeiros, A. A. A functional classification scheme

References

- for beta-lactamases and its correlation with molecular structure. *Antimicrobial agents and chemotherapy* **39**, 1211-1233 (1995).
- 58 Lohans, C. T., Brem, J. & Schofield, C. J. New Delhi metallo- β -lactamase 1 catalyzes avibactam and aztreonam hydrolysis. *Antimicrobial agents and chemotherapy* **61**, 10.1128/aac.01224-01217 (2017).
- 59 Poeylout-Palena, A. A. *et al.* A minimalistic approach to identify substrate binding features in B1 metallo- β -lactamases. *Bioorganic & medicinal chemistry letters* **17**, 5171-5174 (2007).
- 60 Hackbarth, C. J., Unsal, I. & Chambers, H. F. Cloning and sequence analysis of a class A beta-lactamase from *Mycobacterium tuberculosis* H37Ra. *Antimicrob Agents Chemother* **41**, 1182-1185, doi:10.1128/aac.41.5.1182 (1997).
- 61 Wang, F., Cassidy, C. & Sacchettini, J. C. Crystal structure and activity studies of the *Mycobacterium tuberculosis* beta-lactamase reveal its critical role in resistance to beta-lactam antibiotics. *Antimicrob Agents Chemother* **50**, 2762-2771, doi:10.1128/AAC.00320-06 (2006).
- 62 Hugonnet, J.-E. & Blanchard, J. S. Irreversible inhibition of the *Mycobacterium tuberculosis* β -lactamase by clavulanate. *Biochemistry* **46**, 11998-12004 (2007).
- 63 Hackbarth, C. J., Unsal, I. & Chambers, H. F. Cloning and sequence analysis of a class A beta-lactamase from *Mycobacterium tuberculosis* H37Ra. *Antimicrobial agents and chemotherapy* **41**, 1182-1185 (1997).
- 64 Lewandowski, E. M. *et al.* Mechanisms of proton relay and product release by Class A β -lactamase at ultrahigh resolution. *The FEBS journal* **285**, 87-100 (2018).
- 65 Pemberton, O. A. *et al.* Mechanism of proton transfer in class A β -lactamase catalysis and inhibition by avibactam. *Proceedings of the National Academy of Sciences* **117**, 5818-5825 (2020).
- 66 Meroueh, S. O., Fisher, J. F., Schlegel, H. B. & Mobashery, S. Ab initio QM/MM study of class A β -lactamase acylation: dual participation of Glu166 and Lys73 in a concerted base promotion of Ser70. *Journal of the American Chemical Society* **127**, 15397-15407 (2005).
- 67 Minasov, G., Wang, X. & Shoichet, B. K. An ultrahigh resolution structure of TEM-1 β -lactamase suggests a role for Glu166 as the general base in acylation. *Journal of the American Chemical Society* **124**, 5333-5340 (2002).
- 68 Hermann, J. C., Hensen, C., Ridder, L., Mulholland, A. J. & Höltje, H.-D. Mechanisms of antibiotic resistance: QM/MM modeling of the acylation

References

- reaction of a class A β -lactamase with benzylpenicillin. *Journal of the American Chemical Society* **127**, 4454-4465 (2005).
- 69 Hermann, J. C., Pradon, J., Harvey, J. N. & Mulholland, A. J. High level QM/MM modeling of the formation of the tetrahedral intermediate in the acylation of wild type and K73A mutant TEM-1 class A β -lactamase. *The Journal of Physical Chemistry A* **113**, 11984-11994 (2009).
- 70 Faraci, W. S. & Pratt, R. F. Mechanism of inhibition of the PC1. beta.-lactamase of *Staphylococcus aureus* by cephalosporins: importance of the 3'-leaving group. *Biochemistry* **24**, 903-910 (1985).
- 71 Faraci, W. S. & Pratt, R. Mechanism of inhibition of RTEM-2. beta.-lactamase by cephamycins: relative importance of the 7. alpha.-methoxy group and the 3'leaving group. *Biochemistry* **25**, 2934-2941 (1986).
- 72 Wang, F., Cassidy, C. & Sacchettini, J. C. Crystal structure and activity studies of the *Mycobacterium tuberculosis* β -lactamase reveal its critical role in resistance to β -lactam antibiotics. *Antimicrobial agents and chemotherapy* **50**, 2762-2771 (2006).
- 73 Ambler, R. P. *et al.* A standard numbering scheme for the class A beta-lactamases. *Biochemical Journal* **276**, 269 (1991).
- 74 Maveyraud, L., Pratt, R. & Samama, J.-P. Crystal structure of an acylation transition-state analog of the TEM-1 β -lactamase. Mechanistic implications for class A β -lactamases. *Biochemistry* **37**, 2622-2628 (1998).
- 75 Golemi-Kotra, D. *et al.* The importance of a critical protonation state and the fate of the catalytic steps in class A β -lactamases and penicillin-binding proteins. *Journal of Biological Chemistry* **279**, 34665-34673 (2004).
- 76 Jelsch, C., Mourey, L., Masson, J. M. & Samama, J. P. Crystal structure of *Escherichia coli* TEM1 β -lactamase at 1.8 Å resolution. *Proteins: Structure, Function, and Bioinformatics* **16**, 364-383 (1993).
- 77 Elings, W. *et al.* Phosphate Promotes the Recovery of *Mycobacterium tuberculosis* β -Lactamase from Clavulanic Acid Inhibition. *Biochemistry* **56**, 6257-6267, doi:10.1021/acs.biochem.7b00556 (2017).
- 78 Patel, M. P. *et al.* Synergistic effects of functionally distinct substitutions in β -lactamase variants shed light on the evolution of bacterial drug resistance. *Journal of Biological Chemistry* **293**, 17971-17984 (2018).
- 79 Fleming, A. On the antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of *B. influenzae*. *British journal of experimental pathology* **10**, 226 (1929).
- 80 Brotzu, G. Research on a new antibiotic. *Publications of the Cagliari Institute*

- of Hygiene, 5-19 (1948).
- 81 Brown, A. *et al.* Naturally-occurring β -lactamase inhibitors with antibacterial activity. *The Journal of antibiotics* **29**, 668-669 (1976).
- 82 Raj, G. (Springer, Singapore, 2021).
- 83 Domachowske, J. & Suryadevara, M. *Clinical infectious diseases study guide: a problem-based approach*. (Springer Nature, 2020).
- 84 Tartaglione, T. A. & Polk, R. E. Review of the new second-generation cephalosporins: cefonicid, ceforanide, and cefuroxime. *Drug intelligence & clinical pharmacy* **19**, 188-198 (1985).
- 85 Barriere, S. L. & Flaherty, J. F. Third-generation cephalosporins: a critical evaluation. *Clinical pharmacy* **3**, 351-373 (1984).
- 86 Trehan, I., Morandi, F., Blaszczak, L. C. & Shoichet, B. K. Using steric hindrance to design new inhibitors of class C β -lactamases. *Chemistry & biology* **9**, 971-980 (2002).
- 87 Knoverek, C. R., Amarasinghe, G. K. & Bowman, G. R. Advanced methods for accessing protein shape-shifting present new therapeutic opportunities. *Trends in biochemical sciences* **44**, 351-364 (2019).
- 88 Saleh, T. & Kalodimos, C. G. Enzymes at work are enzymes in motion. *Science* **355**, 247-248 (2017).
- 89 Yon, J., Perahia, D. & Ghelis, C. Conformational dynamics and enzyme activity. *Biochimie* **80**, 33-42 (1998).
- 90 Petrović, D., Risso, V. A., Kamerlin, S. C. L. & Sanchez-Ruiz, J. M. Conformational dynamics and enzyme evolution. *Journal of the Royal Society Interface* **15**, 20180330 (2018).
- 91 Mittermaier, A. K. & Kay, L. E. Observing biological dynamics at atomic resolution using NMR. *Trends in biochemical sciences* **34**, 601-611 (2009).
- 92 Procko, E. *et al.* Computational design of a protein-based enzyme inhibitor. *Journal of molecular biology* **425**, 3563-3575 (2013).
- 93 Hart, K. M., Ho, C. M., Dutta, S., Gross, M. L. & Bowman, G. R. Modelling proteins' hidden conformations to predict antibiotic resistance. *Nature communications* **7**, 12965 (2016).
- 94 Bowman, G. R., Pande, V. S. & Noé, F. *An introduction to Markov state models and their application to long timescale molecular simulation*. Vol. 797 (Springer Science & Business Media, 2013).
- 95 Knoverek, C. R. *et al.* Opening of a cryptic pocket in β -lactamase increases penicillinase activity. *Proceedings of the National Academy of Sciences* **118**, e2106473118 (2021).

References

- 96 Tokuriki, N. & Tawfik, D. S. Protein dynamism and evolvability. *Science* **324**, 203-207 (2009).
- 97 Davies, J. Inactivation of antibiotics and the dissemination of resistance genes. *Science* **264**, 375-382 (1994).
- 98 Matagne, A., Dubus, A., Galleni, M. & Frère, J.-M. The β -lactamase cycle: a tale of selective pressure and bacterial ingenuity. *Natural product reports* **16**, 1-19 (1999).
- 99 Darby, E. M. *et al.* Molecular mechanisms of antibiotic resistance revisited. *Nature Reviews Microbiology*, 1-16 (2022).
- 100 Papp-Wallace, K. M. *et al.* Exploring the role of the Ω -loop in the evolution of ceftazidime resistance in the PenA β -lactamase from *Burkholderia multivorans*, an important cystic fibrosis pathogen. *Antimicrobial Agents and Chemotherapy* **61**, e01941-01916 (2017).
- 101 Salverda, M. L. M., De Visser, J. A. G. M. & Barlow, M. Natural evolution of TEM-1 β -lactamase: experimental reconstruction and clinical relevance. *FEMS Microbiology Reviews* **34**, 1015-1036, doi:10.1111/j.1574-6976.2010.00222.x (2010).
- 102 Bonnet, R. *et al.* Novel cefotaximase (CTX-M-16) with increased catalytic efficiency due to substitution Asp-240 \rightarrow Gly. *Antimicrobial agents and chemotherapy* **45**, 2269-2275 (2001).
- 103 Poirel, L., Gniadkowski, M. & Nordmann, P. Biochemical analysis of the ceftazidime-hydrolysing extended-spectrum β -lactamase CTX-M-15 and of its structurally related β -lactamase CTX-M-3. *Journal of Antimicrobial Chemotherapy* **50**, 1031-1034 (2002).
- 104 Bonnet, R. *et al.* Effect of D240G substitution in a novel ESBL CTX-M-27. *Journal of Antimicrobial Chemotherapy* **52**, 29-35 (2003).
- 105 Munday, C. J. *et al.* Molecular and kinetic comparison of the novel extended-spectrum β -lactamases CTX-M-25 and CTX-M-26. *Antimicrobial agents and chemotherapy* **48**, 4829-4834 (2004).
- 106 Delmas, J. *et al.* Structure and dynamics of CTX-M enzymes reveal insights into substrate accommodation by extended-spectrum β -lactamases. *Journal of molecular biology* **375**, 192-201 (2008).
- 107 Ghiglione, B. *et al.* Defining substrate specificity in the CTX-M family: the role of Asp240 in ceftazidime hydrolysis. *Antimicrobial Agents and Chemotherapy* **62**, e00116-00118 (2018).
- 108 Papp-Wallace, K. M. *et al.* Exposing a β -lactamase “twist”: the mechanistic

- basis for the high level of ceftazidime resistance in the C69F variant of the *Burkholderia pseudomallei* PenI β -lactamase. *Antimicrobial Agents and Chemotherapy* **60**, 777-788 (2016).
- 109 Palzkill, T., Le, Q. Q., Venkatachalam, K., LaRocco, M. & Ocera, H. Evolution of antibiotic resistance: several different amino acid substitutions in an active site loop alter the substrate profile of β -lactamase. *Molecular microbiology* **12**, 217-229 (1994).
- 110 Petrosino, J. F. & Palzkill, T. Systematic mutagenesis of the active site omega loop of TEM-1 beta-lactamase. *Journal of bacteriology* **178**, 1821-1828 (1996).
- 111 Banerjee, S., Pieper, U., Kapadia, G., Pannell, L. K. & Herzberg, O. Role of the Ω -loop in the activity, substrate specificity, and structure of class A β -lactamase. *Biochemistry* **37**, 3286-3296 (1998).
- 112 Vakulenko, S. B. *et al.* Effects on substrate profile by mutational substitutions at positions 164 and 179 of the class A TEMpUC19 β -lactamase from *Escherichia coli*. *Journal of Biological Chemistry* **274**, 23052-23060 (1999).
- 113 Levitt, P. S. *et al.* Exploring the role of a conserved class A residue in the Ω -loop of KPC-2 β -lactamase: a mechanism for ceftazidime hydrolysis. *Journal of Biological Chemistry* **287**, 31783-31793 (2012).
- 114 Poirel, L. *et al.* CTX-M-type extended-spectrum β -lactamase that hydrolyzes ceftazidime through a single amino acid substitution in the omega loop. *Antimicrobial Agents and Chemotherapy* **45**, 3355-3361 (2001).
- 115 Yi, H. *et al.* Twelve positions in a β -lactamase that can expand its substrate spectrum with a single amino acid substitution. *PLoS One* **7**, e37585 (2012).
- 116 Tribuddharat, C., Moore, R. A., Baker, P. & Woods, D. E. *Burkholderia pseudomallei* class A β -lactamase mutations that confer selective resistance against ceftazidime or clavulanic acid inhibition. *Antimicrobial agents and chemotherapy* **47**, 2082-2087 (2003).
- 117 Morosini, M. I. *et al.* New extended-spectrum TEM-type beta-lactamase from *Salmonella enterica* subsp. *enterica* isolated in a nosocomial outbreak. *Antimicrobial agents and chemotherapy* **39**, 458-461 (1995).
- 118 Jones, C. H. *et al.* Pyrosequencing using the single-nucleotide polymorphism protocol for rapid determination of TEM-and SHV-type extended-spectrum β -lactamases in clinical isolates and identification of the novel β -lactamase genes bla SHV-48, bla SHV-105, and bla TEM-155. *Antimicrobial agents and chemotherapy* **53**, 977-986 (2009).

References

- 119 Delmas, J., Robin, F., Bittar, F., Chanal, C. & Bonnet, R. Unexpected enzyme TEM-126: role of mutation Asp179Glu. *Antimicrobial agents and chemotherapy* **49**, 4280-4287 (2005).
- 120 Rasheed, J. *et al.* Evolution of extended-spectrum beta-lactam resistance (SHV-8) in a strain of Escherichia coli during multiple episodes of bacteremia. *Antimicrobial Agents and Chemotherapy* **41**, 647-653 (1997).
- 121 Arlet, G., Rousseau, M. & Philippon, A. Substitution of alanine for aspartate at position 179 in the SHV-6 extended-spectrum β -lactamase. *FEMS microbiology letters* **152**, 163-167 (1997).
- 122 Stepanova, M. N. *et al.* Convergent in vivo and in vitro selection of ceftazidime resistance mutations at position 167 of CTX-M-3 β -lactamase in hypermutable Escherichia coli strains. *Antimicrobial agents and chemotherapy* **52**, 1297-1301 (2008).
- 123 Sarovich, D. S. *et al.* Development of ceftazidime resistance in an acute Burkholderia pseudomallei infection. *Infection and drug resistance*, 129-132 (2012).
- 124 Mammeri, H., Poirel, L. & Nordmann, P. In Vivo Selection of a Chromosomally Encoded β -Lactamase Variant Conferring Ceftazidime Resistance in Klebsiella oxytoca. *Antimicrobial agents and chemotherapy* **47**, 3739-3742 (2003).
- 125 Nijhuis, R. *et al.* OXY-2-15, a novel variant showing increased ceftazidime hydrolytic activity. *Journal of Antimicrobial Chemotherapy* **70**, 1429-1433 (2015).
- 126 Raquet, X. *et al.* TEM β -lactamase mutants hydrolysing third-generation cephalosporins: a kinetic and molecular modelling analysis. *Journal of molecular biology* **244**, 625-639 (1994).
- 127 Herzberg, O., Kapadia, G., Blanco, B., Smith, T. S. & Coulson, A. Structural basis for the inactivation of the P54 mutant of beta.-lactamase from Staphylococcus aureus PC1. *Biochemistry* **30**, 9503-9509 (1991).
- 128 Barnes, M. D. *et al.* Klebsiella pneumoniae carbapenemase-2 (KPC-2), substitutions at Ambler position Asp179, and resistance to ceftazidime-avibactam: unique antibiotic-resistant phenotypes emerge from β -lactamase protein engineering. *MBio* **8**, e00528-00517 (2017).
- 129 Alsenani, T. *et al.* Structural characterization of the D179N and D179Y variants of KPC-2 β -lactamase: Ω -loop destabilization as a mechanism of resistance to ceftazidime-avibactam. *Antimicrobial Agents and Chemotherapy* **66**, e02414-02421 (2022).

References

- 130 Bös, F. & Pleiss, J. r. Conserved water molecules stabilize the Ω -loop in class A β -lactamases. *Antimicrobial agents and chemotherapy* **52**, 1072-1079 (2008).
- 131 Kuzin, A. P. *et al.* Structure of the SHV-1 β -lactamase. *Biochemistry* **38**, 5720-5727 (1999).
- 132 Hwang, J., Cho, K.-H., Song, H., Yi, H. & Kim, H. S. Deletion mutations conferring substrate spectrum extension in the class A β -lactamase. *Antimicrobial Agents and Chemotherapy* **58**, 6265-6269 (2014).
- 133 Stojanoski, V. *et al.* A triple mutant in the Ω -loop of TEM-1 β -lactamase changes the substrate profile via a large conformational change and an altered general base for catalysis. *Journal of Biological Chemistry* **290**, 10382-10394 (2015).
- 134 Novais, A. *et al.* Evolutionary trajectories of beta-lactamase CTX-M-1 cluster enzymes: predicting antibiotic resistance. *PLoS pathogens* **6**, e1000735 (2010).
- 135 Porter, J. R. *et al.* Cooperative changes in solvent exposure identify cryptic pockets, switches, and allosteric coupling. *Biophysical Journal* **116**, 818-830 (2019).
- 136 Patel, M. P. *et al.* The drug-resistant variant P167S expands the substrate profile of CTX-M β -lactamases for oxyimino-cephalosporin antibiotics by enlarging the active site upon acylation. *Biochemistry* **56**, 3443-3453 (2017).
- 137 Hobson, C. A. *et al.* Klebsiella pneumoniae carbapenemase variants resistant to ceftazidime-avibactam: an evolutionary overview. *Antimicrobial Agents and Chemotherapy* **66**, e00447-00422 (2022).
- 138 Brown, C. A. *et al.* Antagonism between substitutions in β -lactamase explains a path not taken in the evolution of bacterial drug resistance. *Journal of Biological Chemistry* **295**, 7376-7390 (2020).
- 139 Stürenburg, E., Kühn, A., Mack, D. & Laufs, R. A novel extended-spectrum β -lactamase CTX-M-23 with a P167T substitution in the active-site omega loop associated with ceftazidime resistance. *Journal of Antimicrobial Chemotherapy* **54**, 406-409 (2004).
- 140 Hart, K. M., Ho, C. M., Dutta, S., Gross, M. L. & Bowman, G. R. Modelling proteins' hidden conformations to predict antibiotic resistance. *Nature communications* **7**, 1-10 (2016).
- 141 Strynadka, N. C. *et al.* Molecular structure of the acyl-enzyme intermediate in β -lactam hydrolysis at 1.7 Å resolution. *Nature* **359**, 700-705 (1992).

References

- 142 Strynadka, N. C. *et al.* Structural and kinetic characterization of a β -lactamase-inhibitor protein. *Nature* **368**, 657-660 (1994).
- 143 Basra, P. *et al.* Fitness tradeoffs of antibiotic resistance in extraintestinal pathogenic *Escherichia coli*. *Genome biology and evolution* **10**, 667-679 (2018).
- 144 Soroka, D. *et al.* Hydrolysis of clavulanate by *Mycobacterium tuberculosis* β -lactamase BlaC harboring a canonical SDN motif. *Antimicrobial agents and chemotherapy* **59**, 5714-5720 (2015).
- 145 Citri, N., Samuni, A. & Zyk, N. Acquisition of substrate-specific parameters during the catalytic reaction of penicillinase. *Proceedings of the National Academy of Sciences* **73**, 1048-1052 (1976).
- 146 KIENER, P. A., KNOTT-HUNZIKER, V., PETURSSON, S. & WALEY, S. G. Mechanism of Substrate-induced Inactivation of β -Lactamase I. *European Journal of Biochemistry* **109**, 575-580 (1980).
- 147 Frieden, C. Kinetic aspects of regulation of metabolic processes: The hysteretic enzyme concept. *Journal of Biological Chemistry* **245**, 5788-5799 (1970).
- 148 Page, M. The kinetics of non-stoichiometric bursts of β -lactam hydrolysis catalysed by class C β -lactamases. *Biochemical journal* **295**, 295-304 (1993).
- 149 Elings, W. *et al.* Phosphate promotes the recovery of *Mycobacterium tuberculosis* β -lactamase from clavulanic acid inhibition. *Biochemistry* **56**, 6257-6267 (2017).
- 150 Shen, Y., Delaglio, F., Cornilescu, G. & Bax, A. TALOS+: a hybrid method for predicting protein backbone torsion angles from NMR chemical shifts. *Journal of biomolecular NMR* **44**, 213-223 (2009).
- 151 Berjanskii, M. V. & Wishart, D. S. A simple method to predict protein flexibility using secondary chemical shifts. *Journal of the American Chemical Society* **127**, 14970-14971 (2005).
- 152 Tassoni, R., Blok, A., Pannu, N. S. & Ubbink, M. New conformations of acylation adducts of inhibitors of β -lactamase from *Mycobacterium tuberculosis*. *Biochemistry* **58**, 997-1009 (2019).
- 153 Yuan, Z., Bailey, T. L. & Teasdale, R. D. Prediction of protein B-factor profiles. *Proteins: Structure, Function, and Bioinformatics* **58**, 905-912 (2005).
- 154 Mura, C. Development & Implementation of a PyMOL'putty'Representation. *arXiv preprint arXiv:1407.5211* (2014).
- 155 Delmas, J., Robin, F., Carvalho, F., Mongaret, C. & Bonnet, R. Prediction of

References

- the evolution of ceftazidime resistance in extended-spectrum β -lactamase CTX-M-9. *Antimicrobial agents and chemotherapy* **50**, 731-738 (2006).
- 156 Chudyk, E. I. *et al.* QM/MM simulations reveal the determinants of carbapenemase activity in class A β -lactamases. *ACS Infectious Diseases* **8**, 1521-1532 (2022).
- 157 Wang, X., Minasov, G. & Shoichet, B. K. Evolution of an antibiotic resistance enzyme constrained by stability and activity trade-offs. *Journal of molecular biology* **320**, 85-95 (2002).
- 158 van Alen, I. *et al.* The G132S mutation enhances the resistance of Mycobacterium tuberculosis β -lactamase against sulbactam. *Biochemistry* **60**, 2236-2245 (2021).
- 159 Chikunova, A. *et al.* Conserved residues Glu37 and Trp229 play an essential role in protein folding of β -lactamase. *The FEBS Journal* **288**, 5708-5722 (2021).
- 160 Bush, K., Freudenberg, J. S. & Sykes, R. B. Interaction of azthreonam and related monobactams with beta-lactamases from gram-negative bacteria. *Antimicrobial Agents and Chemotherapy* **22**, 414-420 (1982).
- 161 Vranken, W. F. *et al.* The CCPN data model for NMR spectroscopy: development of a software pipeline. *Proteins: structure, function, and bioinformatics* **59**, 687-696 (2005).
- 162 Kannt, A., Young, S. & Bendall, D. S. The role of acidic residues of plastocyanin in its interaction with cytochrome *f*. *Biochimica et Biophysica Acta (BBA)-Bioenergetics* **1277**, 115-126 (1996).
- 163 Newman, J. *et al.* Towards rationalization of crystallization screening for small-to medium-sized academic laboratories: the PACT/JCSG+ strategy. *Acta Crystallographica Section D: Biological Crystallography* **61**, 1426-1431 (2005).
- 164 Svensson, O., Gilski, M., Nurizzo, D. & Bowler, M. W. Multi-position data collection and dynamic beam sizing: recent improvements to the automatic data-collection algorithms on MASSIF-1. *Acta Crystallographica Section D: Structural Biology* **74**, 433-440 (2018).
- 165 Kabsch, W. xds. *Acta Crystallographica Section D: Biological Crystallography* **66**, 125-132 (2010).
- 166 Evans, P. R. An introduction to data reduction: space-group determination, scaling and intensity statistics. *Acta Crystallographica Section D: Biological Crystallography* **67**, 282-292 (2011).

References

- 167 Winn, M. D. *et al.* Overview of the CCP4 suite and current developments. *Acta Crystallographica Section D: Biological Crystallography* **67**, 235-242 (2011).
- 168 Joosten, R. P., Long, F., Murshudov, G. N. & Perrakis, A. The PDB_REDO server for macromolecular structure model optimization. *IUCrJ* **1**, 213-220 (2014).
- 169 Wei, G., Xi, W., Nussinov, R. & Ma, B. Protein ensembles: how does nature harness thermodynamic fluctuations for life? The diverse functional roles of conformational ensembles in the cell. *Chemical reviews* **116**, 6516-6551 (2016).
- 170 Motlagh, H. N., Wrabl, J. O., Li, J. & Hilser, V. J. The ensemble nature of allostery. *Nature* **508**, 331-339 (2014).
- 171 Mendoza-Martinez, C. *et al.* Energetics of a protein disorder–order transition in small molecule recognition. *Chemical Science* **13**, 5220-5229 (2022).
- 172 Schulenburg, C. & Hilvert, D. Protein conformational disorder and enzyme catalysis. *Dynamics in enzyme catalysis*, 41-67 (2013).
- 173 Kohen, A. Role of dynamics in enzyme catalysis: substantial versus semantic controversies. *Accounts of chemical research* **48**, 466-473 (2015).
- 174 Bhabha, G. *et al.* A dynamic knockout reveals that conformational fluctuations influence the chemical step of enzyme catalysis. *Science* **332**, 234-238 (2011).
- 175 Gerstein, M., Lesk, A. M. & Chothia, C. Structural mechanisms for domain movements in proteins. *Biochemistry* **33**, 6739-6749 (1994).
- 176 Krefß, N., Halder, J. M., Rapp, L. R. & Hauer, B. Unlocked potential of dynamic elements in protein structures: channels and loops. *Current opinion in chemical biology* **47**, 109-116 (2018).
- 177 Papaleo, E. *et al.* The role of protein loops and linkers in conformational dynamics and allostery. *Chemical reviews* **116**, 6391-6423 (2016).
- 178 Egorov, A., Rubtsova, M., Grigorenko, V., Uporov, I. & Veselovsky, A. The role of the Ω -loop in regulation of the catalytic activity of TEM-type β -lactamases. *Biomolecules* **9**, 854 (2019).
- 179 Sun, J. *et al.* Enhanced activity against a third-generation cephalosporin by destabilization of the active site of a class A beta-lactamase. *International Journal of Biological Macromolecules*, 126160 (2023).
- 180 Escobar, W. A., Tan, A. K., Lewis, E. R. & Fink, A. L. Site-Directed Mutagenesis of Glutamate-166 in beta.-Lactamase Leads to a Branched Path Mechanism. *Biochemistry* **33**, 7619-7626 (1994).

References

- 181 Gibson, R., Christensen, H. & Waley, S. Site-directed mutagenesis of β -
lactamase I. Single and double mutants of Glu-166 and Lys-73. *Biochemical*
journal **272**, 613-619 (1990).
- 182 Leung, Y.-C., Robinson, C. V., Aplin, R. T. & Waley, S. G. Site-directed
mutagenesis of β -lactamase I: role of Glu-166. *Biochemical journal* **299**,
671-678 (1994).
- 183 Tremblay, L. W., Xu, H. & Blanchard, J. S. Structures of the Michaelis
complex (1.2 Å) and the covalent acyl intermediate (2.0 Å) of cefamandole
bound in the active sites of the *Mycobacterium tuberculosis* β -lactamase
K73A and E166A mutants. *Biochemistry* **49**, 9685-9687 (2010).
- 184 Tomanicek, S. J. *et al.* Neutron diffraction studies of a class A β -lactamase
Toho-1 E166A/R274N/R276N triple mutant. *Journal of molecular biology*
396, 1070-1080 (2010).
- 185 Shimamura, T. *et al.* Acyl-intermediate structures of the extended-spectrum
class A β -lactamase, Toho-1, in complex with cefotaxime, cephalothin, and
benzylpenicillin. *Journal of biological chemistry* **277**, 46601-46608 (2002).
- 186 Totir, M. A. *et al.* Effect of the inhibitor-resistant M69V substitution on the
structures and populations of trans-enamine β -lactamase intermediates.
Biochemistry **45**, 11895-11904 (2006).
- 187 Soroka, D. *et al.* Characterization of broad-spectrum *Mycobacterium*
abscessus class A β -lactamase. *Journal of Antimicrobial Chemotherapy* **69**,
691-696 (2014).
- 188 van Alen, I. *et al.* Asp179 in the class A β -lactamase from *Mycobacterium*
tuberculosis is a conserved yet not essential residue due to epistasis. *The*
FEBS Journal (2023).
- 189 Lin, J., Pozharski, E. & Wilson, M. A. Short carboxylic acid-carboxylate
hydrogen bonds can have fully localized protons. *Biochemistry* **56**, 391-402
(2017).
- 190 Sawyer, L. & James, M. N. Carboxyl-carboxylate interactions in proteins.
Nature **295**, 79-80 (1982).
- 191 Dai, S. *et al.* Low-barrier hydrogen bonds in enzyme cooperativity. *Nature*
573, 609-613 (2019).
- 192 Perrin, C. L. & Nielson, J. B. “Strong” hydrogen bonds in chemistry and
biology. *Annual review of physical chemistry* **48**, 511-544 (1997).

References

- 193 Verma, D., Jacobs, D. J. & Livesay, D. R. Variations within class-A β -lactamase physiochemical properties reflect evolutionary and environmental patterns, but not antibiotic specificity. *PLoS computational biology* **9**, e1003155 (2013).
- 194 Lockhart, D. J. & Kim, P. S. Electrostatic screening of charge and dipole interactions with the helix backbone. *Science* **260**, 198-202 (1993).
- 195 Leysse, D. *et al.* Noncovalent complexes of an inactive mutant of CTX-M-9 with the substrate piperacillin and the corresponding product. *Antimicrobial agents and chemotherapy* **55**, 5660-5665 (2011).
- 196 Ibuka, A. *et al.* Crystal structure of the E166A mutant of extended-spectrum β -lactamase Toho-1 at 1.8 Å resolution. *Journal of molecular biology* **285**, 2079-2087 (1999).
- 197 Chen, Y., Delmas, J., Sirot, J., Shoichet, B. & Bonnet, R. Atomic resolution structures of CTX-M beta-lactamases: extended spectrum activities from increased mobility and decreased stability. *J Mol Biol* **348**, 349-362, doi:10.1016/j.jmb.2005.02.010 (2005).
- 198 A T Bouthors, N. D.-B., T Naas, P Nordmann, V Jarlier, and W Sougakoff. Role of residues 104, 164, 166, 238 and 240 in the substrate profile of PER-1 beta-lactamases hydrolyzing third-generation cephalosporins. *Biochem J* **15**, 1443-1449 (1998).
- 199 Judge, A. *et al.* Mapping the determinants of catalysis and substrate specificity of the antibiotic resistance enzyme CTX-M β -lactamase. *Communications Biology* **6**, 35, doi:10.1038/s42003-023-04422-z (2023).
- 200 Barnes, M. D. *et al.* Klebsiella pneumoniae carbapenemase-2 (KPC-2), substitutions at Ambler position Asp179, and resistance to ceftazidime-avibactam: unique antibiotic-resistant phenotypes emerge from β -lactamase protein engineering. *MBio* **8**, 10.1128/mbio.00528-00517 (2017).
- 201 Taracila, M. A. *et al.* Different conformations revealed by NMR underlie resistance to ceftazidime/avibactam and susceptibility to meropenem and imipenem among D179Y variants of KPC β -lactamase. *Antimicrobial Agents and Chemotherapy* **66**, e02124-02121 (2022).
- 202 Castanheira, M. *et al.* Analyses of a ceftazidime-avibactam-resistant *Citrobacter freundii* isolate carrying bla KPC-2 reveals a heterogeneous population and reversible genotype. *Msphere* **3**, 10.1128/msphere.00408-00418 (2018).
- 203 Bonomo, R. A., Rudin, S. D. & Shlaes, D. M. OHIO-1 β -lactamase mutants: Asp179Gly mutation confers resistance to ceftazidime. *FEMS microbiology*

- letters **152**, 275-278 (1997).
- 204 Winkler, M. L., Papp-Wallace, K. M. & Bonomo, R. A. Activity of ceftazidime/avibactam against isogenic strains of *Escherichia coli* containing KPC and SHV β -lactamases with single amino acid substitutions in the Ω -loop. *Journal of antimicrobial chemotherapy* **70**, 2279-2286 (2015).
- 205 Cleland, W. & Kreevoy, M. M. Low-barrier hydrogen bonds and enzymic catalysis. *Science* **264**, 1887-1890 (1994).
- 206 Kemp, M. T., Lewandowski, E. M. & Chen, Y. Low barrier hydrogen bonds in protein structure and function. *Biochimica et Biophysica Acta (BBA)-Proteins and Proteomics* **1869**, 140557 (2021).
- 207 Kemp, M. T. *et al.* Mutation of the conserved Asp-Asp pair impairs the structure, function, and inhibition of CTX-M Class A β -lactamase. *FEBS letters* **595**, 2981-2994 (2021).
- 208 Chikunova, A. & Ubbink, M. The roles of highly conserved, non-catalytic residues in class A β -lactamases. *Protein Science* **31**, e4328 (2022).
- 209 Winn, M. D. *et al.* Overview of the CCP4 suite and current developments. *Acta crystallographica. Section D, Biological crystallography* **67**, 235-242, doi:10.1107/s0907444910045749 (2011).
- 210 McDonough, J. A., Hacker, K. E., Flores, A. R., Pavelka Jr, M. S. & Braunstein, M. The twin-arginine translocation pathway of *Mycobacterium smegmatis* is functional and required for the export of mycobacterial β -lactamases. *Journal of bacteriology* **187**, 7667-7679 (2005).
- 211 Raran-Kurussi, S., Cherry, S., Zhang, D. & Waugh, D. S. Removal of affinity tags with TEV protease. *Heterologous Gene Expression in E. coli: Methods and Protocols*, 221-230 (2017).
- 212 Bershtein, S., Segal, M., Bekerman, R., Tokuriki, N. & Tawfik, D. S. Robustness–epistasis link shapes the fitness landscape of a randomly drifting protein. *Nature* **444**, 929-932 (2006).
- 213 Bloom, J. D. *et al.* Thermodynamic prediction of protein neutrality. *Proceedings of the National Academy of Sciences* **102**, 606-611 (2005).
- 214 Razali, R. & Budiman, C. Basic principle and protocols of directed evolution error-prone PCR for enzyme engineering. *TECHNIQUES IN MOLECULAR BIOLOGY*, 95.
- 215 Edwards, J. R. & Betts, M. J. Carbapenems: the pinnacle of the β -lactam antibiotics or room for improvement? *Journal of Antimicrobial Chemotherapy* **45**, 1-4 (2000).

References

- 216 Klibanov, A. M. Why are enzymes less active in organic solvents than in water? *Trends in biotechnology* **15**, 97-101 (1997).
- 217 Littlechild, J. A. Enzymes from extreme environments and their industrial applications. *Frontiers in bioengineering and biotechnology* **3**, 161 (2015).
- 218 Renata, H., Wang, Z. J. & Arnold, F. H. Expanding the enzyme universe: accessing non-natural reactions by mechanism-guided directed evolution. *Angewandte Chemie International Edition* **54**, 3351-3367 (2015).
- 219 Stiffler, M. A., Hekstra, D. R. & Ranganathan, R. Evolvability as a function of purifying selection in TEM-1 β -lactamase. *Cell* **160**, 882-892 (2015).
- 220 Shao, Z. & Arnold, F. H. Engineering new functions and altering existing functions. *Current Opinion in Structural Biology* **6**, 513-518 (1996).
- 221 Bowman, G. R., Huang, X. & Pande, V. S. Network models for molecular kinetics and their initial applications to human health. *Cell research* **20**, 622-630 (2010).
- 222 Chodera, J. D. & Noé, F. Markov state models of biomolecular conformational dynamics. *Current opinion in structural biology* **25**, 135-144 (2014).
- 223 Huang, S. Y. & Zou, X. Ensemble docking of multiple protein structures: considering protein structural variations in molecular docking. *Proteins: Structure, Function, and Bioinformatics* **66**, 399-421 (2007).
- 224 Campbell, A. J., Lamb, M. L. & Joseph-McCarthy, D. Ensemble-based docking using biased molecular dynamics. *Journal of chemical information and modeling* **54**, 2127-2138 (2014).
- 225 Olmos, J. L. *et al.* Enzyme intermediates captured “on the fly” by mix-and-inject serial crystallography. *BMC Biology* **16**, 59, doi:10.1186/s12915-018-0524-5 (2018).
- 226 Kupitz, C. *et al.* Structural enzymology using X-ray free electron lasers. *Structural dynamics (Melville, N.Y.)* **4**, 044003, doi:10.1063/1.4972069 (2017).
- 227 Malla, T. N. *et al.* Heterogeneity in M. tuberculosis β -lactamase inhibition by Sulbactam. *Nature Communications* **14**, 5507, doi:10.1038/s41467-023-41246-1 (2023).
- 228 Gottlieb, T. & Nimmo, G. R. Antibiotic resistance is an emerging threat to public health: an urgent call to action at the Antimicrobial Resistance Summit 2011. *Med J Aust* **194**, 281-283 (2011).
- 229 Ferri, M., Ranucci, E., Romagnoli, P. & Giaccone, V. Antimicrobial

References

- resistance: A global emerging threat to public health systems. *Critical reviews in food science and nutrition* **57**, 2857-2876 (2017).
- 230 Terreni, M., Taccani, M. & Pregnolato, M. New antibiotics for multidrug-resistant bacterial strains: latest research developments and future perspectives. *Molecules* **26**, 2671 (2021).
- 231 Mancuso, G., Midiri, A., Gerace, E. & Biondo, C. Bacterial antibiotic resistance: The most critical pathogens. *Pathogens* **10**, 1310 (2021).
- 232 Broach, J. R. & Thorner, J. High-throughput screening for drug discovery. *Nature* **384**, 14-16 (1996).
- 233 Feller, G., Sonnet, P. & Gerday, C. The beta-lactamase secreted by the antarctic psychrophile *Psychrobacter immobilis* A8. *Applied and environmental microbiology* **61**, 4474-4476 (1995).
- 234 Hsieh, W.-S., Wang, N.-Y., Feng, J.-A., Weng, L.-C. & Wu, H.-H. Identification of DHA-23, a novel plasmid-mediated and inducible AmpC beta-lactamase from Enterobacteriaceae in Northern Taiwan. *Frontiers in Microbiology* **6**, 436 (2015).

